Antipsychotic trials in schizophrenia from India: A systematic review and Meta-analysis

Author(s): S Grover1, S Sarkar2
1Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160 012, India 2Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry-605 006, India

Correspondence Address:
S Grover Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160 012 India E-mail: [email protected]

Ethnic and regional variations have been found in the pharmacological treatment response. Though many efficacy studies have been conducted in India for antipsychotic treatment modalities of schizophrenia, there is a lack meta-analytic data of the existing literature from India. This study aimed to conduct a systematic review and meta-analysis of the antipsychotic treatment trials of schizophrenia in the Indian context. All controlled trials from India evaluating the clinical efficacy of antipsychotics in patients with schizophrenia were evaluated and 28 trials were included in the metanalysis. Effect sizes were computed using Cohen's 'd' and risk of bias was evaluated. Meta analysis revealed superiority of first generation antipsychotics over placebo (mean effect size of 1.387, confidence interval of 1.127 to 1.648). Second generation antipsychotics were marginally better than first generation antipsychotics (effect size 0.106, confidence intervals 0.009 to 0.204). There was improvement in the methodology of the trials over time (Kendall tau=0.289, P=0.049), though no statistically significant increase in trial duration and sample size was noted. There is lack of data on long term efficacy of antipsychotic in schizophrenia from India. First generation antipsychotics have demonstrated benefits over placebo in patients with schizophrenia in the Indian context, though marginally lesser than second generation ones.

Share this